The goal of the project is to develop a rapid in vitro screening assay for detection of cancer biomarkers in urine and blood.
The aim i s testing and optimization of nanoparticle sensors, based on cyanine dyes that are chemically linked to Fe/Fe3O4 nanoparticles via protease-selective consensus (cleavage) sequences. The focus is on the quantitative determination of active cancer-specific proteases in urine and blood via simple fluorescence measurements. The severing from the nanoparticle stops the efficient fluorescence quenching of the organic luminophore by the nanoparticle, thus allowing the detection of the protease activity. The matrix metalloproteinases, urokinase-type plasminogen activator, and cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore, serve as markers for cell survival/tumor progression, angiogenesis, and tissue remodeling/ invasion. The focus will be on pancreatic cancer, and the studies will be done on urine and blood from 30 patients and 12 healthy individuals. Measuring twelve proteases in total that are linked to pancreatic cancer progression will allow us to obtain statistically significant measurements within 1 hour.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research – Phase I (N43)
Project #
261201100069C-0-0-1
Application #
8341497
Study Section
Project Start
2011-09-15
Project End
2012-06-14
Budget Start
Budget End
Support Year
Fiscal Year
2011
Total Cost
$200,000
Indirect Cost
Name
Nanoscale Materials, Inc.
Department
Type
DUNS #
946856804
City
Manhattan
State
KS
Country
United States
Zip Code
66502